Abstract--Novel derivatives of 5-(substituted)benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted)phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted) phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)-diones (8a-l) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from 9 different organs. The tested compounds have showed good inhibitory effect at the ovarian cancer (IGROV1) cell line. A significant inhibition for (RXF393) renal cancer cells was observed with series 3 compounds, while in the other two series 6 and 8, there was a significant inhibition of ovarian cancer cells (OVCAR-8) and melanoma cells (SK-MEL-2). Interestingly; beside the strong inhibition of compound 3q to IGROV1 and RXF393 cells, a great inhibition (199.62 %) for (M14) Melanoma cells was observed at the tested concentration (10 µM). ADME-T and pharmacophore prediction methodology were used to study the antitumor activity of the most active compounds and to identify the structural features required for antitumor activity.
Introduction
Cancer is continuing to be a major health problem in developing as well as developed countries [1, 2] .
Surpassing heart diseases, it is taking the position number one killer due to various worldwide factors. administration of these agents, which indicates a different metabolic fate from that of Sulofenur ( Figure   1 ) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . On the other hand, over the past few years, much interest has been given to the chemotherapeutic activity of hydantoins [27] [28] [29] [30] [31] . Quinazolinediones [32, 33] and pyrimidinetriones [34, 35] as potential anticancer agents.
In view of the previous rationale and in continuation of an ongoing program aiming at finding new structure leads with potential chemotherapeutic activities, new series of 5-(substituted) benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted) phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)-diones (8a-l) have been synthesized and screened for cytotoxic activity ( Figure 1 ). These series comprise the derived N 1 ,N 3 -disubstituted sulfonylurea pharmacophores that are structurally related to sulofenur A and its cyclic form D (Figure 1 ). The thrust of efforts in the derivatization of such type of compounds focused mainly on the aryl moiety of the sulfonamide portion of the diarylsulfonylureas. In the present study, such arylsulfonylurea moiety was incorporated basically as a part of the cyclic structures of hydantoin because of the reported potential anticancer activity of this ring system hoping to induce some biological synergism. In addition, ring replacement of the hydantoin with pyrimidinetrione and quinazolinedione functionality was considered as an interesting structure variation in order to study the influence of such modification on the anticipated antitumor activity. The substitution pattern at the aryl part of the diarylsulfonylurea pharmacophores was selected so as to confer different electronic environment that would affect the lipophilicity, and hence the activity of the target molecules. The objective of forming these hybrids is an attempt to reach an active antitumor agent with potentiated activity and selectivity toward cancerous cells. Moreover ADME-T and pharmacophore prediction methodology were used to identify the structural features required for the antitumor properties of these new series.
Results and discussion
2.1. Chemistry 2.1.1. Synthesis of compounds 3a-r (Scheme 1, Table 1 ).
Scheme 1 outlines the synthetic pathway used to obtain compounds (3a-r). The starting material 5-(substituted)benzylideneimidazolidine-2,4-diones (2a-f) were prepared by allowing hydantoin 1 to condense with the corresponding aromatic aldehydes in glacial acetic acid and in the presence of fused sodium acetate as a condensing agent [36] . Upon mixing of 2 with the appropriate arylsulfonyl chloride and K 2 CO 3 in acetone:water (1:1); 5-(substituted)benzylidene-3-(4-substituted)
phenylsulfonylimidazolidine-2,4-diones (3a-r) were obtained in relatively good yield. Although geometrical isomerism (E/Z isomers) was possible because of the restricted rotation about the exocyclic C=C bond of the arylidene hydantoins, all the derivatives prepared in this study were obtained exclusively in the Z-form as confirmed by the analytical data. In all the IR spectra of the prepared arylidenehydantoins (2a-f), and their subsequent arylsulfonyl derivatives (3a-r), the stretching of the C=C bond appeared in a higher frequency region (1660-1675 cm -1 ) compared to those expected for the E-form (1630-1640 cm -1 ) [37] . Furthermore; the H 1 -NMR spectra of the prepared arylidene hydantoins have showed that the most diagnostic olefinic proton, H6 (-CH=) was deshielded more (δ= 6.4-7.0 ppm)
as expected in the Z-form, relative to the slightly shielded proton of the E-form (δ= 6.2-6.3 ppm). This deshielding of the olefinic proton is caused by the anisotropic effect exerted by the nearby C4 carbonyl group in the Z-isomer [37] .
Synthesis of compounds 6a-l (Scheme 2, Table 2).
1-(4-substituted)phenylureas (4a-d); which were prepared according to Hofmann [38, 39] procedure by reacting the aromatic amine with potassium cyanate in water and in the presence of excess acetic acid;
were treated with diethyl malonate in the presence of sodium ethoxide/absolute ethanol to afford 1-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (5a-d) [40] . As previously mentioned under the preparation of compounds 3a-r; compounds 6a-l were prepared by addition of the appropriate arylsulfonyl chloride to a stirred solution of 5a-d and K 2 CO 3 in acetone: water (1:1).
2.1.3.
Synthesis of compounds 8a-l (Scheme 3, Table 3 ).
3-(4-substituted)phenylquinazoline-2,4(1H,3H)-diones (7a-d) were prepared by fusing anthranilic acid with 1-(4-substituted)phenylureas (4a-d) [41] . The synthesis of 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)-diones (8a-l) was performed via the reaction of 3-(4-substituted)phenylquinazoline-2,4(1H,3H)-diones (7a-d) with sodium tert-butoxide in tert-butanol to induce salt formation, then the separated salt was refluxed with an equivalent amount of the appropriate arylsulfonyl chloride in tert-butanol to yield the target products 8a-l.
Biological activity

In vitro antitumor evaluation
The Thirteen compounds indicated in (Figures 2 and 3 ; Tables 4 and 5) were selected by National
Cancer Institute, Bethesda, Maryland, USA on the basis of degree of the structure variation and computer modeling techniques for evaluation of their antineoplastic activity. The selected compounds were subjected to in vitro anticancer assay against tumor cells in a full panel of 60-cell lines taken from 9 different organs (lung, colon, breast, ovary, blood, kidney, skin, prostate and brain). The compounds were tested at a single dose concentration of 10 µM, and the percentages of growth inhibitions over the sixty tested cell lines were determined. The percentages of growth inhibitions over the most sensitive 5-cell lines are shown in figure 2 and table 4.
Structural activity relationship
By investigating the variation in selectivity of the tested compounds over the full panel of cell lines, it was revealed that nearly all of the compounds belonging to the three series (compounds 3, 6 & 8) show significant inhibition for the ovarian cancer cell line (IGROV1). The percentages of inhibition for (IGROV1) ovarian cancer reached 100% in a number of the tested derivatives ( Figure 2 , Table 4 ).
However; a distinguish in selectivity was observed between the first series (compounds 3), and the second and third series (compounds 6 and 8). In series 3 , a significant inhibition for (RXF393) renal cancer cells (76.2 -96.5 %) was observed, while in both of the other two series 6 and 8, there was a significant inhibition for another type of ovarian cancer cells (OVCAR-8; 33.2 -58.9 %) and melanoma cells (SK-MEL-2; 61.0 -79.3 %). The agreement between the three series in the inhibition of (IGROV1) ovarian cancer cells could be correlated to a similar inhibitory mechanism related to the common structural feature in the three series (the diarylsulfonyl urea structure), while the variation in selectivity over RXF393, OVCAR-8 and SK-MEL-2 cell lines is probably caused by the differences in the hydrocarbon skeleton holding the cyclic urea structure in the three series. These variations could be also correlated to the small difference in the distance between the cores of the two aryl moieties of the diarylsulfonylurea structure, where this distance is almost the same in compounds 6a-l and 8a-l, while a little bit longer in compounds 3a-r. This variation in distance can account for the similar inhibitory profiles for series 6 and 8, and its variation in the compounds belonging to series 3. An odd result was observed with compound 3q (Figure 3 , Table 5 ), where beside the strong inhibition of IGROV1 cells (97.89 %) and RXF393 cells (95.74 %), a great inhibition (199.62 %) for M14 Melanoma cells was observed at the tested concentration (10 µM). This great inhibition at the mentioned concentration indicates a great potency for the compound with a strong lethal effect over (M14) melanoma cells (99.6% lethality), and suggests an IC 50 value in the nanomolar scale.
Molecular modeling Results
Modeling studies are required in order to construct molecular models that incorporate all experimental evidence reported. These models are necessary to obtain a consistent and more precise picture of the biological active molecules at the atomic level and furthermore, provide new insights that can be used to design novel therapeutic agents.
Conformational analysis
In an attempt to gain a better insight on the molecular structures of the active compounds 3p, 3q, 6k and 8b compared with the least active species 3b, 6b and 8j as representative examples; conformational analysis of the target compounds has been performed using the MMFF94 force-field [42, 43] (calculations in vacuo, bond dipole option for electrostatics, Polak-Ribiere algorithm, RMS gradient of 0.01 kcal/Å mol) implemented in MOE 2009.10 [44] . The most stable conformer was fully optimized by AM1 [45] semi-empirical molecular orbital calculation ( Figure 4 ). Calculations at the AM1 level were considered in order to determine relative energies of the E-and Z-isomers of 5-arylidenehydantoin derivatives (3). It was found that the Z-isomer is approximately more stable by more than 3~4 kcal/mol and thus no double bond isomerisation is anticipated ( Figure 4 ) [46] . Moreover the bond distances between N and SO 2 was found to be 1.67 Å, and a twisting of c.a. 34° between the arylidene moiety and hydantoin plane was also found [46] . As clear from the calculations; series 3 compounds exhibit compounds should present good passive oral absorption and differences in their bioactivity cannot be attributed to this property.
The introduction of cyclic ring fragments incorporating the arylsulfonylurea core and the variation of ring size and the substituents on these fragments have allowed us to evaluate the influence of lipophilicity and steric parameters at the pharmacophoric part of the molecules. (Table 6 ). [49, 50] To estimate the prospect of series 3, 6 and 8 compounds as antitumor agents compared with the reported antitumor agents A, D and E; their drug-likeliness were calculated according to absorption, distribution, metabolism, elimination, and toxicity (ADME-T) program, and defined human intestinal absorption (HIA) model [49] . It was predicted that the examined compounds could be transported across the intestinal epithelium, they probably have high affinity to the plasma proteins, and they can cross the blood-brain barrier and are of medium aqueous soluble. The values of HIA, protein binding, BBB crossing and solubility prediction for all compounds are presented in Table 7 . In general, all compounds presented some advantages and disadvantages when compared to each other. No marked differences in health effects and in rodent toxicity profiles were observed among the compounds. However, the absorption related parameters call for attention, since the promising compounds 3 and 6 were calculated to be at least as soluble as the reported compounds, and are predicted to have oral bioavailability and absorption significantly higher than that of the reported antitumor agents A, D and E. These values are also comparable (marginally inferior or superior) to those obtained from series 8 compounds. The present results suggest an optimal pharmacokinetic profile. Accordingly; it can be deduced from these results that the pharmacokinetic profile of diarylsulfonylureas is affected and modified by the presence of arylsulfonyl moiety connected to heterocyclic ring systems. [51, 52] A molecular modeling experiment was carried out to develop a hypothetical pharmacophore model for the antitumor activity aiming to study the fitting of the designed compounds to this pharmacophore. A ligand-based pharmacophore model was developed using a training set of nine diarylsulfonylureas of diverse chemical structures including compounds A-E ( Figure 6 ), in addition to compounds 3h, 3n, 6b
ADME-Tox evaluation
Pharmacophore modelling
and 8a. The generated hypothetical pharmacophore ( Figure 6 ) showed nine overlapping points with similar chemical properties in the training set; F1: a hydrogen bond acceptor center; F2: an aromatic or hydrophobic center with two parallel places "F3 and F5" for Pi orbital accommodation; F4: an aromatic center with a H-bond donor group; F6: a hydrophobic center; and F7: a second H-bond acceptor center.
Fitting of the designed active compounds 3p, 3q, 6k and 8b to the pharmacophore revealed the presence of the appropriate chemical groups superimposed on the pharmacophoric elements ( Figures 6 and 7 ).
The diaryl tail represents the aromatic ring with its Pi orbitals properly oriented to fit to F2, F3 and F5.
Also, N-CO-N and C-CO-C of the ring fragment are H-bond acceptors corresponding to F1. The hydrogen bond acceptor sulfonyl group was found to be fit into F6; it is worthy to mention that this moiety was perfect in adjusting the distance between the other groups in the molecule. This pharmacophoric assumption was in consistence with the reported results for the antitumor arylsylfonylureas [26, 53, 54] .
Conclusion
The present work has lead to the development of novel antitumor molecules and some of which have shown promising antitumor activities. As evident from the experimental and calculated data, the structural features (pharmacophores) essential for the antitumor activity of this series are as follows; (1) a cyclic urea that is an essential backbone that carries the recognition feature for biological activity, (2) the presence of arylsulfonyl moiety at the 1-position in case of series 3 and the 3-position in case of series 6 and 8 of cyclic urea core, (3) the two aryl groups of the diarylsulfonylurea skeleton should reside in a certain distance, ranging between 8.7-9.5Å. The new cyclic arylsulfonylureas prepared in this work have good physical properties that qualify them to have good pharmacokinetics and drug bioavailability. They are fully compatible with Lipinski's rule of five (low molecular weight, favourable
ClogP, favourable hydrogen bond-donating and accepting capabilities). They have a simple synthetic access and thus low production costs. Further optimization and pharmacokinetic profiling of these series are currently ongoing.
Experimental
Chemistry
All melting points ( [36] , 4a-d [38, 39] , 5a-d [40] , and 7a-d [41] have been synthesized according to the reported procedures.
General procedure for the synthesis of compounds 3a-r.
A mixture of compounds 2a-f (0.01 mol) and K 2 CO 3 (0.69 g, 0.005 mol) was stirred in acetone/water solvent system (1:1; 30 mL) at room temperature for 20 minutes. The reaction mixture was then filtered and to the clear filtrate, a solution of the appropriate aryl sulfonyl chloride (0.012 mol) in acetone/water system (1:1; 5 mL) was added dropwise over a period of 20 minutes. The resulted mixture was further stirred for 24 hours at room temperature. The separated solid was then filtered, washed with cold water, dried and crystallized from ethanol. The yield percentages, melting points, molecular formulae and micro-analytical data for (compounds 3a-r) are shown in table 1. 
5-Benzylidene-3-phenylsulfonylimidazolidine-2,4-diones
5-(3-Nitrobenzylidene)-3-(4-methylphenylsulfonyl)imidazolidine-2,4-diones
1-(4-
Chlorophenyl
1-(4-Methylphenyl)-3-(4-chlorophenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-triones
1-(4-Methylphenyl)-3-(4-methylphenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-triones (6i)
:
1-(4-Methoxyphenyl)-3-phenylsulfonylpyrimidine-2,4,6-(1H,3H,5H)-triones (6j)
1-(4-Methoxyphenyl)-3-(4-chlorophenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-triones
1-(4-Methoxyphenyl)-3-(4-methylphenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-triones
General procedure for the synthesis of compounds 8a-l.
The appropriate compound 3a-d (0.01 mol) was added in one portion to a solution of metallic sodium (0.345 g, 0.015 mol) in tert-butanol (30 mL). The reaction mixture was heated under reflux for 6 hours.
The precipitated salt was filtered while hot, washed with hot tert-butanol (50 mL) and dried. To a suspension of the separated salt (0.005 mol) in tert-butanol (20 mL); the appropriate aryl sulfonyl chloride (0.006 mol) in tert-butanol (5 mL) was added dropwise while heating and stirring. The reaction mixture was heated under reflux for 12 hours. The solvent was evaporated under reduced pressure, and the obtained solid was stirred with aqueous NaOH solution (5%, 100 mL) for 30 minutes. The separated solid was filtered, washed with water, dried and crystallized from ethanol. The yield percentages, melting points, molecular formulae and micro-analytical data (for compounds 8a-l are shown in table 3. 
3-Phenyl-1-phenylsulfonylquinazoline-2,4(1H,3H)-diones
3-Phenyl-1-(4-methylphenylsulfonyl)quinazoline-2,4(1H,3H)-diones
3-(4-Chlorophenyl)-1-(4-methylphenylsulfonyl)quinazoline-2,4(1H,3H)-diones
3-(4-Methylphenyl)-1-phenylsulfonylquinazoline-2,4(1H,3H)-diones
3-(4-Methylphenyl)-1-(4-methylphenylsulfonyl)quinazoline-2,4(1H,3H)-diones
Biological evaluation
The 
Molecular modeling methods
General methodology:
All molecular modelling calculations were performed using "Molecular Operating Environment (MOE) version 2008.10", Chemical Computing Group Inc., running on "Windows Vista" operating system installed on an Intel core 2du PC with a 1.8 MHz processor and 1000 Mb RAM.
Alignment of the training set compounds:
The training set compounds, consisting of nine diarylsulfonylureas of diverse chemical structures including compounds A-E, in addition to, compounds 3h, 3n, 6b and 8a, were built using the builder interface of the MOE software. The compounds were aligned using the flexible alignment tool of the program adjusting the energy cut off to 10 kcal/mol and root mean square deviation (RMSD) tolerance to 0.5. The stochastic conformation search option was used as the method of alignment.
Target compounds optimization:
Conformational analyses of the built molecules were performed in a two-step procedure. First, the target compounds were subjected to energy minimization tool using the included MOPAC 7.0. The geometry of the compounds was optimized with the semiemperical AM1 Hamiltonian using Restricted HartreeFock (RHF) and RMS gradient of 0.05 Kcal/mol. Then, the produced model was subjected to the 'Systematic Conformational Search' of the MOE. All items were set as default with RMS gradient of 0.01 Kcal/mol and RMS distance of 0.1 Ǻ. The obtained data were then saved into a MDB file to be used in the pharmacophore fitting calculations.
Pharmacophore Building:
A pharmacophore model was created using the 'Pharmacophore Query Editor'. The aligned training set compounds were used as the template for building the model. The settings of the software parameters were adjusted to: 'Unified' as the scheme of annotation 'Consensus method' for model building.
Tolerance was set to 1.2 Ǻ and the threshold was set to 50%. The produced model was used for testing compound pharmacophore fitting and further calculations.
Fitting of the target compounds on the built model:
Using the generated pharmacophore model and the saved conformations of each molecule; the fitting of the target compounds into the model was tested. The root mean square deviation value for each conformer was calculated and the one having the lowest RMSD value was taken for further visual and energy inspection.
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